Mometasone
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Mometasone: From Allergic Nasal Conditions to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Mometasone is a corticosteroid that is marketed in Singapore as a nasal spray, and it is used clinically for allergic rhinitis, nasal polyposis and asthma, and topically for allergic skin disorders. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma. Evidence is very limited: 0 clinical trials and 2 case reports are currently available, so this is essentially a model prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records (the general clinical use of mometasone is allergic rhinitis, nasal polyposis, asthma and allergic skin disorders) |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, mometasone is a potent corticosteroid that acts on the glucocorticoid receptor (NR3C1). Its effects include anti-inflammatory, immunosuppressive and antiproliferative actions.
Topical corticosteroids are a recognised skin-directed therapy for early-stage mycosis fungoides, the most common primary cutaneous T-cell lymphoma. They are thought to reduce inflammatory T-cell infiltrates and may induce lymphocyte apoptosis. This gives a plausible class-level rationale.
This reasoning comes from general corticosteroid knowledge, not from mometasone-specific data. The very high TxGNN score is a model output only. The Singapore products are nasal sprays, which are not a route suited to skin lymphoma, so the topical route would need separate consideration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40821495 | 2025 | Case report | Proceedings (Baylor Univ. Med. Cent.) | Cutaneous pseudolymphoma (a benign mimic of lymphoma) that did not respond to mometasone and tacrolimus; treated with tapinarof. It does not support mometasone's efficacy. |
| 25442255 | 2015 | Case report | Journal of Cutaneous Pathology | Childhood CD8+CD56+ mycosis fungoides with a cytotoxic immunophenotype; shows the disease is rare in children and often diagnosed late. The abstract provided does not establish a mometasone effect. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15328P | MOMETASONE SANDOZ NASAL SPRAY 0.05% | Spray, suspension | Not stated in the available record |
| SIN16523P | RYALTRIS NASAL SPRAY 600/25MCG | Spray, suspension | Not stated in the available record |
Safety Considerations
- Drug Interactions: The only entry is pharmacological: mometasone acts on the glucocorticoid receptor (NR3C1). No specific drug-drug interactions were identified.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score and a class-level mechanistic argument. No clinical trials exist, and the two case reports do not show a benefit from mometasone. The Singapore products are nasal sprays, not skin-directed formulations.
To proceed, the following is needed:
- Mometasone-specific clinical data in cutaneous T-cell lymphoma, particularly mycosis fungoides
- Detailed mechanism of action data
- Package insert warnings and contraindications from the HSA website
- Assessment of route and formulation compatibility (topical versus nasal)
- Approved indication text for the two Singapore licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.